secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quanterix Corp (QTRX)
CIK:        0001503274
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001104659-22-028337
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quanterix Q4 rev +35% non-GAAP, CEO Hrusovsky becomes Exec Chair, Toloue CEO, Lilly deal $11M
--------------------------------------------------------------------------------

- Q4 GAAP total revenue $30.3M (+16% YoY); non-GAAP total revenue $29.3M (+35% YoY).
- FY 2021 GAAP total revenue $110.6M (+28% YoY); product revenue $81.1M (+84% YoY).
- CEO Kevin Hrusovsky becomes Executive Chairman; President Masoud Toloue succeeds as CEO and joins Board, effective April 25, 2022.
- Collaboration with Eli Lilly: non-exclusive license to P-tau217 antibody technology; Lilly funds $11M development this year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503274/000110465922028337/0001104659-22-028337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503274/000110465922028337/tm226991d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-028337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer